Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BFRA

Biofrontera (BFRA) Stock Price, News & Analysis

Biofrontera logo

About Biofrontera Stock (NASDAQ:BFRA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.51
$2.78
50-Day Range
$2.50
$3.60
52-Week Range
$2.09
$7.54
Volume
7,263 shs
Average Volume
27,512 shs
Market Capitalization
$73.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Remove Ads
Receive BFRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRA Stock News Headlines

Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Q4 2024 Biofrontera Inc Earnings Call
Biofrontera completes patient enrollment in Phase 3 study of Ameluz
See More Headlines

BFRA Stock Analysis - Frequently Asked Questions

Biofrontera AG (NASDAQ:BFRA) announced its earnings results on Wednesday, November, 24th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The company had revenue of $6.34 million for the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%.

Biofrontera (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB).

Company Calendar

Last Earnings
11/24/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BFRA
Employees
138
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.19 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
7.43

Miscellaneous

Free Float
N/A
Market Cap
$73.73 million
Optionable
Not Optionable
Beta
1.02
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:BFRA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners